Document is current
Any future updates will be listed below
-
Authors
Lingasamy, Prakash
Tobi, Allan
Kurm, Kaarel
Tammik, Olav
Teesalu, Tambet
-
Funding
Funding for this research was provided by:
Eesti Teadusagentuur (PRG230 and PRG1788, PRG230 and PRG1788, PRG230 and PRG1788, PRG230 and PRG1788, PRG230 and PRG1788)
EuronanomedIII projects (ECM-CART, ECM-CART, ECM-CART, ECM-CART, ECM-CART)
iNanoGun and TRANSCAN3 project (ReachGLIO, ReachGLIO, ReachGLIO, ReachGLIO, ReachGLIO)
- License Information
-
More Information
Article History
Received: 31 December 2024
Accepted: 9 July 2025
First Online: 11 August 2025
Competing interests
: T.T. and P.L. hold a patent on the PL2 peptide (“Bi-Specific Extracellular Matrix Binding Peptides and Methods of Use Thereof”, WO. patent no. WO 2020/161602 A1), and TT is an inventor of CendR peptides. Other authors declare that they have no competing interests.
: The fresh surgical ovarian carcinoma samples were obtained under protocols approved by the Ethics Committee of the University of Tartu, Estonia (permit #243/T27). Additionally, informed consent was obtained from all the patients, and methods for using human samples were carried out under relevant guidelines and regulations accordance with the Declaration of Helsinki.
: Animal experimentation procedures were approved by the Estonian Ministry of Agriculture, Committee of Animal Experimentation, projects #42 and #48 (IACUC). We confirm that all methods were performed in accordance with the relevant guidelines and regulations. We confirm that the study was conducted in accordance with the ARRIVE guidelines.
